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https://doi.org/10.1016/j.cell.2020.06.036SUMMARYInflammatory bowel disease (IBD) is a chronic inflammatory disease associatedwith increased risk of gastro-
intestinal cancers. We whole-genome sequenced 446 colonic crypts from 46 IBD patients and compared
these to 412 crypts from 41 non-IBD controls from our previous publication on the mutation landscape of
the normal colon. The average mutation rate of affected colonic epithelial cells is 2.4-fold that of healthy co-
lon, and this increase is mostly driven by acceleration of mutational processes ubiquitously observed in
normal colon. In contrast to the normal colon, where clonal expansions outside the confines of the crypt
are rare, we observed widespread millimeter-scale clonal expansions. We discovered non-synonymous mu-
tations in ARID1A, FBXW7, PIGR, ZC3H12A, and genes in the interleukin 17 and Toll-like receptor pathways,
under positive selection in IBD. These results suggest distinct selection mechanisms in the colitis-affected
colon and that somatic mutations potentially play a causal role in IBD pathogenesis.INTRODUCTION
Inflammatory bowel disease (IBD) is a debilitating disease char-
acterized by repeated flares of intestinal inflammation. The two
major subtypes of IBD, Crohn’s disease (CD) and ulcerative co-
litis (UC), are distinguished by the location, continuity, and nature
of the inflammatory lesions. UC affects only the large intestine,
spreading continuously from the distal to proximal colon,
whereas CDmost commonly affects the small and large intestine
and is characterized by discontinuous patches of inflammation.
In addition to the significant morbidity associated with the dis-
ease, IBD patients have a 1.7-fold increased risk of developing
gastrointestinal cancers compared to the general population.
Cancer risk is associated with the duration, extent, and severity
of disease, and cancers tend to occur earlier in life in IBD patients
(Lutgens et al., 2013; Beaugerie and Itzkowitz, 2015; Adami
et al., 2016). As a result, patients require regular endoscopic
screening and may undergo prophylactic colectomy to mitigate
this risk (Beaugerie and Itzkowitz, 2015; Adami et al., 2016).
That somatic mutations contribute to the development of can-
cer is well established, but their patterns, burden, and functional672 Cell 182, 672–684, August 6, 2020 ª 2020 The Author(s). Publish
This is an open access article under the CC BY license (http://creativeconsequences in diseases other than cancer have not been
extensively studied. Methodological developments have now
enabled the analysis of polyclonal somatic tissues, allowing
characterization of somatic mutations in normal tissues such
as skin (Martincorena et al., 2015), esophagus (Martincorena
et al., 2018; Yokoyama et al., 2019), endometrium (Moore
et al., 2020; Suda et al., 2018), lung (Yoshida et al., 2020), and co-
lon (Blokzijl et al., 2016; Lee-Six et al., 2019). In the setting of
non-neoplastic diseases, chronic liver disease has had the
most attention, with studies showing that compared to healthy
liver, hepatic cirrhosis is associated with acquisition of new
mutational processes, increased mutation burden and larger
clonal expansions (Brunner et al., 2019; Kim et al., 2019; Zhu
et al., 2019).
Colonic epithelium is well suited to the study of somatic muta-
tions because of its clonal structure. It is organized into millions
of colonic crypts, finger-like invaginations composed of 2,000
cells (Potten et al., 1992) each extending into the lamina propria
below. At the base of each crypt reside a small number of stem
cells undergoing continuous self-renewal through stochastic cell
divisions (Lopez-Garcia et al., 2010; Snippert et al., 2010). As aed by Elsevier Inc.
commons.org/licenses/by/4.0/).
Figure 1. Mutation Burden in the IBD Colon
(A) Substitution (top) and indel (bottom) burden as a function of age. Each point represents a colonic crypt and is colored by disease status. The line shows the
effect of age on mutation burden as estimated by fitting a linear mixed effects model, correcting for sampling location, sequencing coverage, and the within-
biopsy and within-patient correlation structure, considering both IBD cases and controls. The shaded area represents the 95% confidence interval of the age
effect estimate.
(B) Estimated excess of substitutions (top) and indels (bottom) in crypts from IBD patients as function of disease duration. Shaded area represents the 95%
confidence interval.
(C) A comparison of the effects of age and disease duration on the total mutation burden and on the burden of mutational signatures that associate with IBD
duration. Error bars represent the 95% confidence intervals of the estimates.
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; SBS, single base substitution signature; ID, indel signature.
See also Tables S1 and S2.
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through the entire niche, and the epithelial cells that line the crypt
are the progeny of this single clone. Active IBD disrupts these
normal stem cell dynamics—the epithelial lining is damaged,
the organized crypt structure is ablated, and the barrier between
lumen and mucosa is disrupted.
We hypothesized that the recurrent cycles of inflammation, ul-
ceration, and regeneration seen in IBD could impact the muta-
tional and clonal structure of intestinal epithelial cells. To test
these hypotheses, we isolated and whole-genome sequenced
446 colonic crypts from 46 IBD patients with varying degrees
of colonic inflammation, both active and previous, and
compared themutation burden, clonal structure, mutagen expo-
sure, and driver mutation landscape to colonic crypts from
healthy donors (Lee-Six et al., 2019).
RESULTS
IBD More Than Doubles the Mutation Rate of Normal
Colonic Epithelium
We used laser capture microdissection (LCM) to isolate 446
colonic crypts from endoscopic biopsies taken from 28 UC pa-
tients and 18 CD patients (Table S1). Biopsies were annotated
as never, previously, or actively inflamed at the time of sampling
(STAR Methods). The dissected crypts were whole-genomesequenced to a median depth of 18.2X, allowing us to call so-
matic substitutions and small insertions and deletions (indels)
with high specificity and sensitivity (Figure S1; STAR Methods).
We also called larger copy number changes, somatic retrotrans-
positions, and aneuploidies affecting whole chromosomes or
chromosome arms (Tables S2 and S3; STAR Methods).
To assess if IBD is associated with a difference in the mutation
burden of the colonic epithelium, we combined our data with
data from 412 crypts sequenced as part of our recent study of
somatic mutations in normal colon (Lee-Six et al., 2019) (here-
after referred to as the control data). We fitted linear mixed-ef-
fects models (LMMs) to estimate the independent effects of
age, disease duration, and biopsy location on mutation burden,
while controlling for the within-patient and within-biopsy correla-
tions inherent in our sampling strategy (STARMethods). Disease
duration was included in the model as a proxy for inflammation
exposure. We estimated the effect of IBD to be 55 substitutions
per crypt per year of disease duration (35–75 95%confidence in-
terval [CI], p = 3.1 3 107, LMMs and likelihood ratio test; Fig-
ure 1). These mutations are in addition to the 40 (31–50, 95%
CI) substitutions we estimated are accumulated on average
per year of life under normal conditions, suggesting that muta-
tion rates are increased 2.4-fold in regions of the IBD-affected
colon on average. Compared to controls, patients with IBD had
greater between-patient variance in mutation burden (SD = 776Cell 182, 672–684, August 6, 2020 673
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and controls, p = 4.2 3 108 and p = 1.1 3 1016, respectively;
LMMs and likelihood ratio test) and greater within-patient vari-
ance (SD = 955 versus 407 substitutions and SD = 81 and 18 in-
dels for cases and controls, p = 0.032 and p = 0.0011, respec-
tively). The increased between-patient variance likely reflects
differences in inflammation exposure not captured by disease
duration, because it does not account for variable disease
severity, response to treatment, etc. among patients. The
increased within-patient variance probably reflects region-to-re-
gion differences in disease severity along the colon. We similarly
estimated an increase in the indel burden in IBD, with an excess
of 6.8 indels per crypt per year of IBD (5.0—8.7 95%CI, p = 5.73
1011; Figure 1) in addition to the estimated 1.0 (0.3–1.7 95% CI)
indel that is accumulated per crypt per year of life. As shown in
Figure 1B, a handful of clones and patients had a much higher
mutation burden than expected given their age. This is partially
driven by the effect of smoking and cancer driver status, as dis-
cussed below. The effect of IBD on the mutation burden remains
significant if crypts carrying driver mutations, or the five IBD pa-
tients with the highest mutation burdens, are excluded (p =
0.0014 and 0.0099 for substitutions and p = 6.8 3 106 and
1.1 3 105 for indels, respectively). We found no significant dif-
ference in the mutation burden between UC and CD patients.
Smoking status was available for a subset of the IBD cohort
(35 patients who contributed 362 crypts). In this restricted data-
set, we found an effect of smoking duration of 49 (18–81 95%CI,
p = 0.0024) substitutions and 5.3 (2.3–8.2 95% CI, p = 6.5 3
104) indels per crypt per year of smoking. The effect of disease
duration was unchanged, suggesting this effect is not driven by
differences in smoking habits between cases and controls.
Smoking has been reported to increase the risk of CD and be
protective for UC (Mahid et al., 2006), but we found no interaction
effect between smoking and disease type (p = 0.68). Smoking
status was not available for the control cohort. The full details
of all LMMs are available in a GitHub directory accompanying
this submission (https://github.com/Solafsson/somaticIBD/).
IBD Accelerates Age-Related Mutational Processes
The somatic mutations found in the cells of a colonic crypt reflect
the mutational processes that have acted on the stem cells and
their progenitors since conception. Distinct mutational processes
each leave a characteristic pattern, a mutational signature, within
the genome, distinguished by the specific base changes and their
local sequence context (Alexandrov et al., 2013, 2020). We ex-
tracted mutational signatures jointly for IBD and control crypts
and discovered 12 substitution signatures (SBS) and five indel
signatures (ID), all of which have been previously observed in tis-
sues from individuals without IBD (Figure S2; Table S2; STAR
Methods). Comparing our IBD cases and controls, we found
that 80% of the increase in mutation burden in cases is ex-
plained by signatures that are also found ubiquitously in normal
colon (Blokzijl et al., 2016; Lee-Six et al., 2019). These are substi-
tution signatures 1, 5, and 18 and indel signatures 1 and 2, as
defined by Alexandrov et al. (2020) (Figure 1), which cause an in-
crease of 13 (8–18 95%CI), 23 (15–30 95%CI), and 9 (6–12 95%
CI) substitutions per crypt per year of disease, respectively (p =
2.4 3 107, 1.0 3 107, and 3.2 3 107), and 4.3 (3.3–5.4 95%674 Cell 182, 672–684, August 6, 2020CI) and 1.7 (1.1–2.3, 95% CI) indels per crypt per year, respec-
tively (p = 4.0 3 1012 and p = 9.5 3 108, LMMs and likelihood
ratio tests, see https://github.com/Solafsson/somaticIBD/ for
full details of the models). Substitution signatures 1 and 5 are
clock-like and thought to be associated with cell proliferation,
whereas signature 18 has been linked with reactive oxygen spe-
cies (Alexandrov et al., 2020). The indel signatures ID1 and ID2
are both thought to be the result of polymerase slippage during
DNA replication (Alexandrov et al., 2020).
The remaining 20% of the increase in substitution burden is a
consequence of rarer mutational processes and treatment. For
example, 96 crypts had over 150 mutations attributed to purine
treatment in a subset of seven IBD patients, five of whom have
a documented history of such treatment. However, the number
of mutations attributed to purine was not associated with purine
therapy duration, and some patients showed large mutation bur-
dens despite brief, or indeed no, documented exposure. For
example, one patient received azathioprine for 2 weeks and
mercaptopurine for 2weeks and had significant adverse reactions
to both drugs. This brief treatment resulted in amedian of 204mu-
tations (range: 120–374) attributed to purine treatment in the
crypts from this individual. Other patients had long-term exposure
to azathioprine without accruing any purine-related mutations
(Figure 2B). There was also great within-patient variation in the
burden of the purine signature. The largest range was observed
for patient 40, which has a 7 year history of purine treatment.
The estimated burden of the purine signature in crypts from this
patient ranged from 69–1,005. The reason for this large variation
in purine-related mutation burden remains unknown, although it
is associated with the number of putative cancer drivers (see
below). Thiopurine use has been associated with higher overall
cancer risk in epidemiological studies, but this is mostly driven
by an effect on lymphoid cancers and possibly on urinary tract
cancers, but not colorectal cancers (Pasternak et al., 2013; Adami
et al., 2016). The relationship between purines and colon cancer is
complicated and requires further study. On one hand, our results
show purine-related mutations accumulating in the crypts of a
subset of patients, but on the other hand, effective purine treat-
ment may prevent disease-related mutagenesis.
Five signatures previously discovered in the normal colon
(Lee-Six et al., 2019), SBSA, SBSB, SBSC, IDA, and IDB were
also present in the context of IBD. SBSA and IDA and SBSB
and IDB are highly correlated (Figure S2B) and likely represent
the same underlying mutational processes. SBSA and IDA are
of particular interest because they have recently been shown
to be caused by the genotoxin colibactin, which is produced
by bacteria harboring a polyketide synthases (pks) pathogenicity
island (Pleguezuelos-Manzano et al., 2020). pks+ E. coli have
been reported at increased frequency in IBD (Arthur et al.,
2012), but we found no relationship between SBSA or IDA
burden and disease status or disease duration after correcting
for higher burden of both in the left-side of the colon (the site pri-
marily affected in UC). As in normal colon, SBSA and SBSBwere
primarily found in early branches of the phylogenetic trees (Fig-
ures S3 and S4). Signatures SBSB, SBSC, and SBS32 have
not been reported in studies of sporadic colorectal cancers
(Alexandrov et al., 2020), perhaps due to the comparative
complexity and diversity of cancer mutation profiles. SBS32,
Figure 2. Mutational Signatures in Colonic Crypts
(A) A stacked barplot showing the proportional contribution of single-base-substitution (SBS) signatures (top) and indel (ID) signatures (bottom) to the mutation
burden of each crypt. Crypts are grouped by patient and crypts from CD, UC, and controls are shown separately. Signature nomenclature is the same as in
Alexandrov et al. (2020). The ‘‘Unassigned’’ component represents uncertainty of the signature extraction.
(B) Phylogenetic trees of two patients with widespread ulcerative colitis. The colors of the branches reflect the relative contribution of each mutational signature
extracted for those branches as in (A). The patient on the left has received azathioprine treatment for 10 years but shows no SBS32 burden (dark blue). In contrast,
the patient on the right received azathioprine for 2 weeks and mercaptopurine for 2 weeks and had significant adverse reactions to both drugs. SBS32 is found in
most crypts from this patient. All crypts are from inflamed biopsies.
See also Figure S2 and Table S2.
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therapy and so would not be present in sporadic colorectal can-
cers. These signatures have also not been reported in studies of
colitis-associated colorectal cancers but this is likely due to a
relative lack of power due to the small number of sequenced
exomes (Robles et al., 2016; Baker et al., 2019; Din et al., 2018).
Signatures 2 and 13, which are associated with APOBEC activ-
ity, and signatures 17a and 17b, which are of unknown etiology,
wereactive inasmall numberofcryptswithhighmutationburdens.
SBSB, SBSC, SBS17a/b, and SBS2/SBS13 are too rare for us to
be powered to detect any difference between IBD and controls
or to associate these with any clinical feature documented in our
metadata. Finally,we foundsignature35, associatedwithplatinum
compound therapy, in one patient with a history of platinum treat-ment for squamous cell carcinoma of the tongue. The patient
received 40 mg/m2 of cisplatin therapy on a weekly basis. He
completed three of six planned treatment cycles with therapy
termination due to toxicity. This relatively brief treatment resulted
in a medium of 430 mutations (range: 350–461) per crypt that
were attributed to signature 35, equivalent to10 years of normal
mutagenesis. In crypts from this individual, we also observed a
small number of double base substitutions of CT > AA and CT >
AC classes (median 6, range: 5–13), probably indicative of DBS5,
which has also been linked with platinum treatment.
IBD Associates with the Burden of Structural Variants
We called copy number variants (CNVs), somatic retrotranspo-
sitions, and loss-of-heterozygosity events affecting wholeCell 182, 672–684, August 6, 2020 675
Figure 3. Burden of Structural Variants in Inflammatory Bowel Disease-Affected Colon Compared with IBD-Unaffected Colon
(A) Number of copy number variants in IBD sub-types compared with controls.
(B) Number of somatic retrotranspositions in IBD subtypes compared with controls.
(C) Fraction of crypts with inflammation history that carry chromosomal aneuploidies.
See also Table S3.
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ploidies for simplicity) in both our IBD cases and non-IBD con-
trols. The burden of structural variants is modest in both data-
sets (Figure 3), but for IBD, we identified the occasional clone
that carried a large number of CNVs and retrotranspositions
(Figures 3A and 3B). The numbers of CNVs and retrotranspo-
sitions are associated with IBD duration. We estimated the
CNV mutation rate to be 0.067 CNVs per crypt per year of dis-
ease (0.027–0.11 95% CI, p = 1.1 3 103, likelihood ratio test
of mixed-effects Poisson regressions) and the retrotransposi-
tion mutation rate to be 0.065 (0.018–0.11, 95% CI, p = 6.9 3
103). This corresponds to one CNV per crypt every 14.9 years
of disease duration and one retrotransposition event every
15.4 years of disease duration on average. However, a handful
of clones accumulated many structural variants (SVs),
whereas the majority had none, suggesting that the processes
driving their acquisition may be episodic rather than contin-
uous. This would be in line with findings from other reports
linking rapid accrual of SVs with the transition from normal
to dysplastic mucosa (Baker et al., 2019) and cancers
accruing copy number gains in a punctuated manner (Ger-
stung et al., 2020).676 Cell 182, 672–684, August 6, 2020We found a higher fraction of IBD crypts carrying aneuploidies
than in controls (43/419 comparedwith 13/412, Figure 2C). How-
ever, this was driven by large clones carrying aneuploidies, and
the number of events was not significantly associated with dis-
ease duration (p = 0.42). No type of chromosomal abnormality
differed significantly between UC and CD (p = 0.65, 0.83, and
0.67 for deletions, duplications, and loss-of-heterozygosity,
respectively; binomial mixed effects model). The numbers of
CNVs, retrotranspositions, and aneuploidies are associated
with higher substitution burden (112 [49–175 95% CI, p =
6.4 3 104], 59 [38–81 95% CI, p = 1.5 3 107], and 199
[65–331 95%CI, p = 3.73 103], respectively), and retrotranspo-
sitions and CNVs are associated with higher indel burden
(11 [8–14 95% CI, p = 2.6 3 1012] and 17 [10–24 95% CI,
p = 6.7 3 106], respectively).
IBD Creates a Patchwork of Millimeter-Scale Clones
Colonic crypts divide by a process called crypt fission, whereby
a crypt bifurcates at the base, and branching elongates in a zip-
like manner toward the lumen. This process is relatively rare in
the normal colon, wherein each crypt fissions on average only
once every 27 years (Nicholson et al., 2018; Lee-Six et al.,
(legend on next page)
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expansions in IBD patients, evident of numerous crypt fission
events occurring late in molecular time. We observed several ex-
amples of individual clones spanning entire 2–3 mm endoscopic
biopsies (Figures 4, 5A, S3, and S4). Our ability to estimate clone
sizes is restricted by the small size of the biopsies. However,
when we biopsied the same inflamed or previously inflamed re-
gionmore than once, on only one occasion out of 19 biopsy pairs
did we observe a clone stretching between biopsies that were
taken a few millimeters apart (Figures S3 and S4), whereas
most biopsies contained more than one clone. To improve our
ability to detect larger clones, we sampled three patients more
broadly. Nine biopsies, forming a 33 3 grid with 1 cm separating
biopsies, were obtained from each patient. We dissected 187
crypts from the biopsies and performed whole exome
sequencing on individual crypts. Phylogenetic trees were recon-
structed based on somatic mutations identified (Figure 5B–5D).
Although clonal expansions within biopsies are common, we
found clones extending between neighboring biopsies in only
one of these patients. A substantial body of evidence exists doc-
umenting widespread clonal expansions giving rise to dysplasia
and ultimately to colorectal cancer in IBD (reviewed in Choi et al.,
2017). Colitis-associated colorectal cancers, which are enriched
with synchronous lesions (Lam et al., 2014; Choi et al., 2015),
commonly grow from a background of a pre-cancerous field
that has expanded many centimeters or even the whole length
of the colon (Leedham et al., 2009; Galandiuk et al., 2012). Mu-
tations in TP53 are thought to be especially prominent in the
growth of these clones, but aneuploidies and KRAS mutations
are also commonly observed (Holzmann et al., 1998; Leedham
et al., 2009; Galandiuk et al., 2012). In our material of non-
dysplastic tissue from individuals without colorectal neoplasia,
we find smaller clones and mutations in TP53, KRAS, or APC
are rare. In summary, IBD-affected regions are generally not
dominated by a single major clone, but are more accurately
viewed as an oligoclonal patchwork of clones that often grow
considerably larger than in healthy colon.
Distinct Patterns of Selection in IBD Compared with
Normal Epithelium
The recurrent cycles of inflammation and remission that charac-
terize IBD could create an environment in which clones contain-
ing advantageous mutations may selectively spread in the mu-
cosa. This advantage may manifest either through faster cell
division and elevated crypt fission rate or through increased
resistance to the cytotoxic effects of inflammation. To identify
mutations that likely confer selective advantage on the cell, we
searched for mutations occurring in canonical mutation hotspots
from the Cancer Genome Atlas (Table S4A). This revealed a totalFigure 4. Examples of Clonal Expansions in Three IBD Patients
Top: a phylogenetic tree of crypts sampled from a 66-year-old patient with a 25
crypts from the orange shaded area. The clones highlighted in blue and orange co
difference in the mutation burden of these clones is driven by a local activation of s
of crypts sampled from a 61-year-old patient with a 27-year history of ulcerative
millimeters apart. The accompanying biopsy image shows the crypts from the pu
patient with a 25-year history of Crohn’s disease affecting the colon. A biopsy ov
See also Figures S3 and S4.
678 Cell 182, 672–684, August 6, 2020of 10 missense mutations in KRAS, BRAF, TP53, ERBB2,
ERBB3, and FBXW7 occurring at canonical hotspots (Table
S4B). Additionally, we found a heterozygous nonsense mutation
in APC and frameshift indels in known colorectal tumor suppres-
sors; ATM, SOX9, RNF43, and ZFP36L2, of likely driver status
(Figure 4A; Table S4B). Furthermore, two large-scale deletions
in our dataset overlap known tumor suppressors, PIK3R1 and
CUX1, and are likely drivers. The number of putative cancer
drivers found in a crypt is associated with increased burden of
both substitutions (269 substitutions per driver, 90–447 95%
CI, p = 5.6 3 103) and indels (40 indels per driver, 20–60 95%
CI, p = 1.73 104), as well as with each of the replication-related
signatures (SBS1, SBS5, SBS18, ID1, and ID2; Table S4C).
There was also a significant association with the purine signature
(SBS32). We estimated the burden of purine signature to be
increased by 30 (14–47, 95% CI, p = 3.7 3 104; Figures S5A
and S5B) substitution per driver, suggesting that rapidly dividing
cells may be particularly susceptible to the mutagenic effect of
purine treatment.
To search for genes under positive selection, we assessed the
ratio of non-synonymous to synonymous mutations (dN/dS)
across all IBD crypts, while correcting for regional and context-
dependent variation in mutation rates (Martincorena et al.,
2017). Genes with dN/dS ratios significantly different from 1
are considered to be under selective pressure. This analysis re-
vealed four genes, ARID1A, FBXW7, PIGR, and ZC3H12A, to be
under positive selection in the IBD colon (Figures 6A and S5C;
Table S4B). ARID1A and FBXW7 are well-established tumor
suppressors and are found mutated at similar frequencies in
sporadic- and colitis-associated colorectal cancers (Martincor-
ena et al., 2017; Baker et al., 2019). In several instances, distinct
heterozygousmutations in the same gene were found in different
crypts from the same patient (Figures S3 and S4). For example,
in one patient suffering from pan-colitis, we found four distinct
PIGR mutations in four biopsies from the right, transverse, and
left side of the colon (Figure 6B). We did not detect a significant
signal of selection of mutation in the two genes, AXIN2 or
STAG2, whichwe previously found to be under positive selection
in the normal colon (Lee-Six et al., 2019) (p = 0.98 and 0.74,
respectively) nor was there any evidence of selection of PIGR
or ZC3H12A mutants in the normal colon (Table S5B). We did
not find a significant difference in the mutation burden of any
of these genes between UC and CD, suggesting that similar se-
lection pressures are operative in mucosal tissue in both
diseases.
Recurrent mutations in PIGR and ZC3H12A are of particular
interest because these have not been described in cancer but
have roles in immunoregulation and reflect distinct mechanisms
of positive selection in the IBD colon. PIGR encodes the poly--year history of ulcerative colitis. The accompanying biopsy image shows the
me from the same previously inflamed site and were millimeters apart. A large
ignatures 17a and 17b in the orange shaded clone. Middle: a phylogenetic tree
colitis. The clones highlighted in purple and yellow come from biopsies taken
rple clone. Bottom: a phylogenetic tree of crypts sampled from a 37-year-old
erlaps two clones (in blue and green). Scale bars, 250 mm.
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duced by plasma cells in the mucosal wall across the epithelium
to be secreted into the intestinal lumen (Johansen and Kaetzel,
2011). Pigr knockout mice exhibit decreased epithelial barrier
integrity and increased susceptibility to mucosal infections and
penetration of commensal bacteria into tissues (Johansen
et al., 1999). ZC3H12A encodes an RNase, Regnase-1 (also
known asMCPIP1). It is activated in response to TLR stimulation
and degrades mRNA of many downstream immune signaling
genes (Matsushita et al., 2009), including PIGR (Nakatsuka
et al., 2018), NFKBIZ (Mino et al., 2015), and members of the
interleukin-17 (IL-17) pathway (Garg et al., 2015). Four of themu-
tations in ZC3H12A occur in a DSGxxS motif that, when phos-
phorylated, marks the protein for ubiquitin-mediated degrada-
tion. Mutations of the corresponding residues in mice
attenuate the phosphorylation (Iwasaki et al., 2011) and stabilize
the protein so these are likely gain-of-function.
We next carried out a pathway-level dN/dS analysis, searching
for enrichment of missense and truncating variants across 15
gene sets that were defined a priori because of their relevance
in either colorectal carcinogenesis or IBD pathology (Figure 6C;
Table S5; STAR Methods). We observed a 6.5-fold (1.8–23.6,
95%CI) enrichment of truncating mutations in genes associated
with colorectal cancer (q = 0.011) as well as a 1.9-fold (1.3–2.8,
95%CI) enrichment in genes significant in a pan-cancer analysis
of selection (Priestley et al., 2019) (q = 0.011). Interestingly, the
pathway-level dNdS also revealed a 4.0-fold (1.7–9.4, 95% CI)
enrichment of truncating mutations in the IL-17 signaling
pathway (q = 0.011) and a 3.3-fold (1.6–6.7, 95% CI) enrichment
in Toll-like receptor (TLR) cascades (q = 0.011) with mutations
from both UC and CD derived crypts contributing to the enrich-
ment (Figures S5D).
DISCUSSION
We have used whole-genome sequencing of individual colonic
crypts to provide the most accurate characterization of the so-
matic mutation landscape of the IBD-affected colon to date.
The increased cancer risk of IBD patients results from a combi-
nation of higher mutation rate, particularly of deleterious muta-
tions such as indels, from increased opportunity for clones car-
rying driver mutations to spread outside the confines of the
crypt and from changes to the selective environment of the mu-
cosa. Our results suggest that somatic substitution rate of the
mucosa is accelerated 2.4-fold in disease, and the indel rate is
accelerated as much as 7- fold. This increase is mostly driven
by acceleration of single base substitution signatures 1, 5, and
18 and indel signatures 1 and 2, which are ubiquitous in the
IBD-unaffected colon and are associated with cell proliferation
and metabolic stress. The relatively large increase in the indel
signatures suggests that IBD affected cells are particularly prone
to DNA polymerase slippage during replication. Driver mutations
are enriched in indels and the relatively high indel burden seen in
IBD may help explain the increased risk of neoplasia, although
this could not be directly tested in the present study.
Metabolic stress also results in an increased burden of
somatic structural variants, which nevertheless remain rare in
the IBD-affected mucosa. Structural variants are common incolorectal cancers and thus rapid increase in structural variation
may be a hallmark of neoplastic transition, in line with previous
reports (Baker et al., 2019). Increase in structural variation from
healthy tissue to non-neoplastic disease has also been observed
in liver disease (Brunner et al., 2019).
Colitis-associated colorectal cancers commonly arise from a
background of large clonal fields (Choi et al., 2017). In our sample
of non-dysplastic tissue, we find millimeter scale clonal expan-
sions, although we note that for many inflamed regions, only a
single small biopsy is available that limits our ability to detect
large clones. TP53 and KRAS mutations are thought to be key
events in clonal spread in the IBD mucosa, but although we do
observe a number of canonical cancer driver mutations in genes
including TP53 andKRAS, onlyARID1A and FBXW7 show signif-
icant evidence of positive selection.
Although there is substantial overlap in the driver landscape of
IBD and non-IBD colon, important differences also exist. Our
findings of enrichment of mutations in PIGR, ZC3H12A, and in
the IL-17 and TLR pathways suggest there are distinct selection
mechanisms in the colitis-affected colon, and somatic mutations
potentially play a causal role in the pathogenesis of IBD. While
this work was under review, two studies of somatic mutations
in UC patients from the Japanese population were published
that confirm our findings of positive selection of mutations in
ARID1A, FBXW7,PIGR, ZC3H12A, and in the IL-17 pathway (Ka-
kiuchi et al., 2020; Nanki et al., 2020). Importantly, our study
shows that the same selective pressures are operative in
mucosal tissue in both UC and CD.
The two papers also report mutations in additional genes
includingNFKBIZ, IL17RA, TRAF3IP2, andNOS2. We performed
restricted-hypothesis testing of a set of 13 genes reported in
these other two papers and replicated six at q < 0.05 (Table
S5F). Importantly, the enrichments of truncating mutations we
observe in the IL-17 and TLR pathways, which sharemany genes
in common, are not driven by the genes discussed above
because PIGR, ZC3H12A, NFKBIZ, and NOS2 are not part of
these pathways (according to Reactome), and no mutations
were found in TRAF3IP2. This suggests that additional positively
selected genes related to IL-17 and TLR signaling may be
discovered in the IBD colon as sample size is increased. The dif-
ference in the number of NFKBIZ mutant crypts between the
studies is noticeable. We detected only 3 truncating mutations
in NFKBIZ, which is the most commonly mutated gene in Kakiu-
chi et al. (2020). This is reminiscent of our previous description of
how selection of NOTCH2 mutants in normal skin may vary be-
tween individuals of European and South Asian ancestry (Martin-
corena et al., 2015). Together with our observation that distinct
mutations in the same gene are often found in crypts from the
same individual, this leads us to speculate that differences in
local environment or a person’s genetic background affects
the strength of selective advantage posed by somatic variants
and studies with larger sample sizes may be able to detect those
interactions.We also observe smaller clones than those reported
by Kakiuchi et al. (2020), who document clones spanning many
centimeters in surgically resected colons. We speculate this
may be due to patients undergoing colectomies having a more
severe disease or due to different selection pressures between
populations as mentioned above. Kakiuchi et al. (2020) alsoCell 182, 672–684, August 6, 2020 679
Figure 5. Clonal Structure of the IBD Colon
(A) For pairs of crypts from the same biopsy, the figure shows the number of mutations that are shared between a pair as a fraction of the averagemutation burden
of the two crypts, and this is plotted as a function of the distance between the pair.
(B) A phylogenetic tree showing crypts sampled from 9 biopsies from the sigmoid colon of a 36-year-old male diagnosed with Crohn’s disease 19 years prior to
sampling. Biopsies were taken 1 cm apart in a three by three grid for all the patients in (B)-(D).
(C) A phylogenetic tree showing crypts sampled from 9 biopsies from the rectum of a 71-year-old male diagnosed with ulcerative colitis 4 years prior to sampling.
(D) A phylogenetic tree showing crypts sampled from 9 biopsies from the rectum of a 42-year-old female diagnosed with ulcerative colitis 13 years prior to
sampling.
See also Figures S3 and S4.
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NFKBIZ, may prevent neoplastic transformation, but our data
neither support nor refute this.
In their study, Nanki et al. (2020) show how IL-17A may be
cytotoxic to epithelial cells and argue that clones carrying IL-
17 pathway mutations are able to avert this cytotoxicity and
thereby selectively expand in the inflamed environment. This680 Cell 182, 672–684, August 6, 2020has implications for the direction of effect of these mutations
on IBD pathogenesis, because selective pressure would only
be asserted following disease onset as Th17 cells infiltrate the
tissue and secrete IL-17A in the vicinity of the epithelium. How-
ever, it could also be hypothesized that these mutations play a
causal role in the pathogenesis of IBD through an effect on dys-
biosis. Indeed, the discovery by Nanki et al. (2020) that PIGR
Figure 6. Driver Mutations and Positive Selection in IBD
(A) An oncoplot showing the distribution of potential driver mutations mapped to branches of phylogenetic trees. Each column represents a branch of a
phylogenetic tree and amutation may be found in multiple crypts if the branch precedes a clonal expansion. Branches without potential drivers are not shown for
simplicity. *Genes showing significant enrichment of non-synonymous mutations after Benjamini-Hochberg correction for multiple testing (q < 0.05).
(B) A phylogenetic tree of the crypts dissected from a 38-year-old male suffering from ulcerative colitis for 21 years. Crypts are dissected from five biopsies from
three previously inflamed sites of the colon. Crypts carrying distinct PIGR truncating mutations are found in four of the biopsies and in all three colonic sites.
(legend continued on next page)
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presence of IL-17A may add weight to this hypothesis. Although
ZC3H12A and NFKBIZ are involved in IL-17 signaling, both are
also induced downstream of TLRs (Yamamoto et al., 2004; Mat-
sushita et al., 2009) where they regulate the transcriptional
changes that follow TLR signaling. Disruption of the IL-17
pathway itself may also play a causal role in the disease,
because intestinal epithelial cell-specific knockout of compo-
nents of the IL-17 pathway in mice results in commensal dysbio-
sis through downregulation of Pigr and other genes (Kumar et al.,
2016). Thus, a positive feedback loop may be established, lead-
ing to ever greater spread of a pathogenic clone. It is worth
noting that clinical trials of secukinumab and brodalumab (anti-
IL-17A and anti-IL-17RA antibodies, respectively) for the treat-
ment of CD have been carried out but either show no efficacy
over placebo or worsen the disease (Hueber et al., 2012; Targan
et al., 2016). Case reports of IBD in psoriasis patients receiving
ixekizumab, a second IL-17A antibody, have been reported (Phi-
lipose et al., 2018; Smith et al., 2019), although post hoc analyses
of ixekizumab trials suggest that IBD is a rare adverse outcome
(Reich et al., 2017).
Our understanding of somatic evolution in normal tissues has
improved greatly over the last few years but how and if somatic
evolution contributes to the pathogenesis of complex traits other
than cancer remains poorly understood. Clonal hematopoiesis
has been associated with coronary heart disease (Jaiswal
et al., 2014), and our work suggests that somatic evolution in
the colonic mucosa may initiate, maintain, or perpetuate IBD.
Large-scale analyses of cancers have started to reveal common
themes of cancer evolution across tissues (Gerstung et al.,
2020), and extending this work to other tissues exposed to
chronic inflammation may similarly reveal patterns of remodeling
of the selection landscapes associated with disease, but which
need not drive neoplastic growth. Comparing the evolutionary
forces in the IBDmucosawith those operating in psoriasis, celiac
disease, asthma, and other diseases affecting epithelial cells is
an area of special interest.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
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BAM files containing sequencing data from
crypts isolated from IBD patients.
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(EGA) - accession code EGA: EGAD00001006061
Images of microdissections and physical
distances between crypts.
This paper. Mendeley Data: https://doi.org/
10.17632/x3vsxpspn4.2
BAM files containing sequencing data from
crypts isolated from controls.
Lee-Six et al., 2019 European Genome-phenome Archive
(EGA) - accession codes EGA: EGAD00001004192
and EGA: EGAD00001004193
PCAWG mutational signatures. Alexandrov et al., 2020 https://cancer.sanger.ac.uk/cosmic/
signatures
Software and Algorithms
Algorithms and software for calling somatic
substitutions - CaVEMan.
Cancer Genome Project,
Wellcome Trust Sanger Institute
http://cancerit.github.io/CaVEMan/
Algorithms and software for calling somatic
indels - PIndel.
Cancer Genome Project,
Wellcome Trust Sanger Institute
http://cancerit.github.io/cgpPindel/
Algorithms and software for calling somatic
retrotranspositions - TraFiC-mem.
Rodriguez-Martin et al., 2020 https://gitlab.com/mobilegenomesgroup/
TraFiC
Algorithms and software for calling somatic
copy number changes - BRASS.
Cancer Genome Project,
Wellcome Trust Sanger Institute
https://github.com/cancerit/BRASS
Algorithms and software for calling somatic
copy number changes - ASCAT.
Cancer Genome Project,
Wellcome Trust Sanger Institute
https://github.com/cancerit/ascatNgs
Algorithms and software for constructing
phylogenetic trees - MPBoot.
Hoang et al., 2018 http://www.iqtree.org/mpboot/
Algorithms and software for extracting
mutational signatures - HDP.
Roberts, 2018 https://github.com/nicolaroberts/hdp
Algorithms and software for estimating
dN/dS ratios.
Martincorena et al., 2017 https://github.com/im3sanger/dndscv
Custom scripts documenting all other
analyses.
This paper. https://github.com/Solafsson/somaticIBDRESOURCE AVAILABILITY
Lead Contact
All requests for data and resources should be directed to the Lead Contact, Dr. Carl Anderson (ca3@sanger.ac.uk).
Materials Availability
This study did not generate new unique reagents or other materials.
Data and Code Availability
All sequencing data for the IBD cohort is available via the European Genome Phenome (https://ega-archive.org/). The accession
number for the IBD data reported in this paper is EGA: EGAD00001006061. The accession numbers for the control data are EGA:
EGAD00001004192 and EGA: EGAD00001004193. Phylogenetic trees, pileup read counts, histology images and physical distances
between dissected crypts have been deposited to Mendeley data: https://doi.org/10.17632/x3vsxpspn4.2.
Custom scripts for carrying out the analyses described herein, including fitting of mixed-effect models, selection analyses and
signature extraction, can be found under https://github.com/Solafsson/somaticIBD.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Colonic pinch-biopsies were donated by IBD patients undergoing regular surveillance of their disease at Addenbrooke’s hospital,
Cambridge (Table S1). All samples were obtained with informed consent of the donor and the study was approved by the NationalCell 182, 672–684.e1–e5, August 6, 2020 e1
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OPEN ACCESS ArticleHealth Service (NHS) Research Ethics Committee (Cambridge South, REC ID 17/EE/0338) and by the Wellcome Trust Sanger Insti-
tute Human Materials and Data Management Committee (approval number 17/113). We have complied with all relevant ethical
regulations.
All donors are of white-European ancestry. The time between clinical diagnosis and date of biopsy was used to define the disease
duration of a given individual. We added six months to this number for all patients because symptoms often precede diagnosis by
several months and to avoid setting the disease duration to zero for patients who donated samples at the time of diagnosis. Time of
purine treatment was estimated by consulting electronic health records from NHS databases. Biopsies were annotated as never,
previously or actively inflamed using all available clinical data and NHS histopathology archives. The biopsy images (or an image
of a second biopsy from the same site of the colon) were reviewed by a histopathologist. None of the patients had colorectal cancer,
adenoma or dysplasia. Patients who donated grid biopsies were chosen at random from those who had been diagnosed with IBD for
more than a year, so to allow time for clonal spread to occur.
Biopsies from patients 1-26 were embedded in optimal cutting temperature (OCT) compound and sectioned, stained and fixed as
previously described (Lee-Six et al., 2019). None of the samples were fixed in formalin. Subsequent biopsies were embedded in
paraffin because this better preserved the morphology of the tissue. Biopsies were sectioned (10-20 mm), fixed to 4 mm PEN mem-
brane slides (11600288, Leica) and stained with hematoxylin and eosin. Crypts were dissected using laser capture microdissection
microscopy (LMD7000, Leica) and lyzed using ARCTURUS PicoPure DNA extraction kit (Applied Biosystems) according to the man-
ufacturer’s instructions. DNA libraries were prepared as previously described (Lee-Six et al., 2019).
The control cohort was obtained from our previous publication on somatic mutations in the normal colon (Lee-Six et al., 2019). It
consists of seven deceased organ donors, 31 individuals who underwent colonoscopy following a positive faecal occult blood test in
a screening program (16 of which were not found to have an adenoma or a carcinoma and 15 of which had colorectal carcinoma,
although the biopsies used were distant from these lesions) and three pediatric patients who underwent colonoscopy to exclude
IBD and who were found to have a histologically and macroscopically normal mucosa. We excluded one subject from the control
cohort who had undergone chemotherapy and was a clear outlier in terms of mutation burden and showed an abnormal muta-
tion profile.
We note that the mutation burden of the pediatric subjects is what would be expected given the mutation burden observed in the
other patients in the cohort, and that the crypts dissected from cancer patients did not show a higher mutation burden, distinct muta-
tional processes or distinct driver landscape from biopsies donated from patients without cancer.
METHOD DETAILS
Genome sequencing
Samples from patient 1 through 19 (Table S1) were whole genome sequenced on Illumina XTENmachines as previously described
(Lee-Six et al., 2019). Samples from other patients were whole genome sequenced on Illumina Htp NovaSeq 6000machines using
150bp, paired end reads except for patients 60-62, which were whole exome sequenced on the same platform using the Human All
Exon V5 bait set. Reads were aligned to the human reference genome (NCBI build37) using BWA-MEM.
MUTATION CALLING AND FILTERING
Substitutions
Base substitution calling was carried out in four steps: Discovery, filtering of the discovery set, genotyping and filtering of the geno-
types. Mutations were first called using the Cancer Variants through Expectation Maximization (CaVEMan) algorithm (Jones et al.,
2016). CaveMan uses a Bayesian classifier, incorporating base quality, read position, read orientation andmore, to derive a posterior
probability of all possible genotypes at every candidate site. Out of concern for field cancerization effect, patients 1 through 26, and
patients fromwhich only a few crypts were sequenced, were analyzed using a matched normal sample dissected from non-epithelial
tissue from one of the biopsies. As it became apparent that clones did not stretch between biopsies, we stopped sequencing non-
epithelial tissue control samples from patients if crypts were dissected from multiple biopsies.
The substitution calls were next filtered, as previously described (Lee-Six et al., 2019), to removemapping artifacts, common single
nucleotide polymorphisms and calls associated with the formation of cruciform DNA structures during library preparation. When
matched normal samples were unavailable for the calling (see above), a large number of rarer germline variants remained post
filtering. All sites where a somatic mutation was called in any crypt from a given patient were subsequently genotyped in all other
samples from that patient by constructing read pileups and counting the number of mutant and wild-type reads. Only reads with
a mapping quality of 30 or higher, and bases with a base quality of 30 or higher, were counted.
We next performed an exact binomial test to remove germline variants. True heterozygous germline variants should be present at a
variant allele frequency (VAF) of 0.5 in all samples from an individual. Across all samples from a given individual, we aggregated
variant and read counts at sites where a single nucleotide variant was called in at least one sample. We then used a one-sided exact
binomial test to distinguish germline variants from somatic variants. The null hypothesis was that germline variants were drawn from a
binomial distributionwith a probability of success of 0.5, or 0.95 for the sex chromosomes inmen. The alternative hypothesis was that
these variants were drawn from distributions with a lower probability of success. The resulting p values were corrected for multiplee2 Cell 182, 672–684.e1–e5, August 6, 2020
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been dissected for the patient. For variants classified as somatic, we fitted a beta-binomial distribution to the number of variant sup-
porting reads and total number of reads across crypts from the same patient. For every somatic variant, we determined themaximum
likelihood overdispersion parameter (r) in a grid-based way (ranging the value of r from 106 to 10-0.05). A low overdispersion cap-
tures artifactual variants because they appear to be randomly distributed across samples and can bemodeled as being drawn from a
binomial distribution. In contrast, true somatic variants will be present at a VAF close to 0.5 in some, but not in all crypt genomes, and
are thus best represented by a beta-binomial with a high overdispersion. To distinguish artifacts from true variants, we used r = 0.1 as
a threshold, below which variants were considered artifacts. The code for this filtering approach is an adaptation of the Shearwater
variant caller (Gerstung et al., 2014). Finally, we filtered out variants that were supported by fewer than three reads or where the
sequencing depth was less than five.
Indels
Short deletions and insertions were called using the Pindel algorithm (Ye et al., 2009). We applied the same restrictions on median
VAF and read counts as for substitutions, and germline indel calls were filtered using the same binomial filters as described above.
Sensitivity analysis
To estimate sensitivity we dissected and sequenced five crypts twice. Assuming the same sensitivity in both samples, a maximum
likelihood estimate for the sensitivity when mutations not present in either sample go unobserved is:
S =
23 n2
n1 + 23n2Where n2 is the number of mutations called in both samples and n1 is the sum of mutations called in only one sample. As sensitivity
depends on coverage, which is uneven for the members of a pair, this estimate should be considered to be a lower bound.
We compared the sensitivity estimates for our five biological duplicates with internal sensitivity estimation for CaveMan (Fig-
ure S2C). This used 170 samples from the same individual sequenced to varying depths and, to remove the effect of clonality of
the sample, estimated the sensitivity for calling heterozygous germline variants in these samples.
Our samples are expected to have slightly lower sensitivity than this estimate for the following reasons:
1. The curve assumes perfect clonality (median VAF of 0.5), but the median-median VAF in the IBD and control cohorts is 0.44.
2. The curve doesn’t capture indels, for which sensitivity is expected to be slightly lower than for substitutions.
3. To increase specificity, this paper required a coverage of 5 and at least 3 reads supporting the mutation, while standard for
CaveMan is coverage of 4 and 2 mutant reads.Constructing phylogenetic trees
We used the MPBoot software (Hoang et al., 2018) to create a phylogenetic tree for each patient. MPBoot uses ultrafast bootstrap
approximation to generate a maximum parsimony consensus tree. We assigned mutations to branches using a maximum likelihood
approach, removing mutations which didn’t adhere to the tree structure (p < 0.01, maximum likelihood estimation).
Structural variants
Copy number variants were called using the BRASS algorithm (https://github.com/cancerit/BRASS) as previously described (Lee-Six
et al., 2019). Calls were filtered using AnnotateBRASS (https://github.com/MathijsSanders/AnnotateBRASS) as previously described
(Moore et al., 2020). When a matched normal sample was not available for a patient, we used a clonally unrelated sample from the
same individual to filter germline variants. All variants passing filters were manually reviewed in a genome browser. For discovery of
deletions at fragile sites of the genome, we manually reviewed the three regions in all the genomes.
Somatic retrotranspostions were called using TraFic algorithm (Rodriguez-Martin et al., 2020). Somatic events supported by read
clusters without exact breakpoints were also included. To further identify somatic transduction events, translocation calls (i.e., read
clusters) related with known L1 germline sources (Rodriguez-Martin et al., 2020) from BRASS algorithm were examined. All somatic
retrotransposition events were manually reviewed.
Chromosome aneuploidies and deletions or duplications affecting large areas of chromosomes or whole chromosome arms were
called using the ASCAT algorithm (Van Loo et al., 2010; Raine et al., 2016).
QUANTIFICATION AND STATISTICAL ANALYSIS
Mutation rate comparisons between IBD patients and controls
Any test for a difference inmutation burden between cohorts must take into account all factors, biological and technical, which corre-
late with disease and/or affect mutation calling sensitivity. For our comparison of IBD and normal, we fitted linear mixed effects
models taking the following factors into account:Cell 182, 672–684.e1–e5, August 6, 2020 e3
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fixed effect for age in the models to account for this.
2. Mutation burden differs for different sectors of the colon (Lee-Six et al., 2019). The IBD cohort is enrichedwith samples from the
left side, as this is the area predominantly affected in UC patients. We included a fixed effect for location within the colon to
account for this.
3. Observations are non-independent. We included in the models random effects for patient and for biopsy, with the random ef-
fect for biopsy nested within that for the patient.
4. Most embryonic mutations will be filtered as germline so at birth themutation count is near zero. We therefore did not include a
random intercept in the models but constrained the intercept to zero. The biological interpretation of this is that there are no
somatic mutations present at birth.
5. The between-patient variance is likely greater in the IBD cohort as patients vary in the duration, extent and severity of their dis-
ease. Thewithin-patient variance is also likely greater in the IBD cohort as biopsies taken from different sites of the colon vary in
their disease exposure, number and duration of flares etc. To model this, we constructed a general positive-definite variance-
covariance matrix for the random effects of patient and biopsy by cohort.
6. Any difference in the clonality of the colon between IBD patients and controls will affect the relative sensitivity to detect somatic
mutations. To account for this, we adjusted the branch lengths of the phylogenetic trees and used the adjusted mutation
counts as the response variable in the models. The adjustment was carried out as follows. Mutations with low variant allele
frequencies (VAFs) will be missed at low coverage. Therefore, for each crypt, we first fitted a truncated binomial distribution
to the VAF distribution of the crypt to estimate the true underlying median VAF (this is different from 0.5 because recent mu-
tations may not yet have been fixed in the stem cell niche, and because of contamination of lymphocytes and other cells from
the lamina propria, which do not carry the same somatic mutations as the epithelial cells). We next simulated 100,000mutation
call attempts by drawing the coverage of each call from a Poisson distribution, with the lambda set as the median coverage of
the sample, and multiplying that with the median VAF estimate from the truncated binomial. The resulting value represents the
number of reads that carry themutated allele. We calculated sensitivity for the sample, Ss, as the fraction of draws that resulted
in four or more mutant reads, which is the number required by CaVEMan to call a mutation. The sensitivity of a branch with n
daughter crypts, Sb, was then calculated as:
Sb = 1 ð1Ss1Þ  :::  ð1SsiÞ  :::  ð1SsnÞ:The adjusted mutation count is thus the observed mutation count divided by the sensitivity of the branch. In this way, the mutation
count of clones formed of stand-alone crypts is augmented more than that of branches with multiple daughter crypts. Even after
these steps, a small but significant effect of coverage remained and a fixed effect for coverage was included in the models.
We compared models thus fitted with ones which additionally included disease duration as a fixed effect using a likelihood ratio
test. The disease durations for never inflamed regions of the colons of IBD patients were set to zero.
As comparatively few structural variants are found in the dataset, we used Poisson regression within a generalized linear mixed
effects framework to test for differences in structural variant number between cases and controls. We included the same random
and fixed effects described above for base substitutions and indels and compared models with and without disease duration using
a likelihood ratio test. The above statistical tests are two-sided as are all statistical tests performed in this manuscript. Full details and
outputs of all statistical models used in this work are available in an R-markdown file accompanying the submission.
Mutational signature extraction and analyses
Define amutational signature as a discrete probability distribution over a set of categorical mutation classes (for example, 96 classes
for single base substitutions - according to the identity of the pyrimidine-mutated base pair, and the base 50 and 30 to it, see Alex-
androv et al. (2013), 2020). We extracted mutational signatures using a hierarchical Dirichlet process (Roberts, 2018) (HDP, see
the hdp R package https://github.com/nicolaroberts/hdp). This has the advantage of allowing simultaneous fitting to existing signa-
tures and discovery of new signatures. We pooled the control and the IBD data and extracted signatures from both datasets as pre-
viously described for indels and single base substitutions separately (Lee-Six et al., 2019). We mapped mutations to branches of a
phylogenetic tree and treated each branch with more than 50 mutations as a sample. We used signatures reported in colorectal can-
cer as priors and also included as priors signature 32, which is attributed to azathioprine therapy (Alexandrov et al., 2020), and signa-
ture 35, attributed to platinum-based chemotherapy, as there are patients in our cohort with history of using these drugs. Using the
PCAWG terminology (Alexandrov et al., 2020), the priors used were SBS1, SBS2, SBS3, SBS5, SBS13, SBS16, SBS17a, SBS17b,
SBS18, SBS25, SBS28, SBS30, SBS32, SBS35,SBS37, SBS40, SBS41, SBS43, SBS45 and SBS49 for substitutions and ID1, ID2,
ID3, ID4, ID5, ID6, ID7, ID8, ID10 and ID14 for indels.
We used expectation maximization to deconvolute the HDP components into known PCAWG signatures. The cosine similarity be-
tween the HDP component corresponding to SBS1was < 0.95 andwe used expectationmaximization to break the component down
into PCAWG signatures.We then reconstituted the components using only those PCAWG signatures that accounted for > 10%of the
mutations (this was done so as to avoid overfitting). This helped resolve the correlation between SBS1, SBS5 and SBS18.Wemergede4 Cell 182, 672–684.e1–e5, August 6, 2020
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ponents had cosine similarity < 0.95 with their corresponding signatures and other PCAWG signatures accounting for > 10% of the
mutations.
Selection analyses
To search for mutations under positive selection, we used the dNdScv method (Martincorena et al., 2017). We included never in-
flamed samples from the IBD cohort in the analysis as some uncertainty existed regarding the annotation of a handful of never-in-
flamed biopsies and we estimated that our analysis would suffer more from potential exclusion of drivers than from inclusion of
more neutral mutations. We used the Benjamini-Hochberg method to correct for multiple testing.
To look for enrichment of mutations in pathways we defined 15 gene-sets (Table S6) as follows. We included all genes found to be
under selection in colorectal cancer (Priestley et al., 2019) and a list of genes significant in a pan-cancer analysis of solid tumors
(Priestley et al., 2019). We also chose a set of cellular pathways known to be important in IBD pathogenesis and epithelial homeo-
stasis. The Reactome database was used to define the pathways (Fabregat et al., 2018), see Table S6 for accession dates and Re-
actome IDs of pathways. We chose the cytokine pathways TNF-Signaling, TNFR2, IL6, TGFb and IL17 for testing. We also defined a
combined list of cytokines which included all of the above as well as IFNg, IL10, IL20, IL23, IL28, and IL36. We also decided to test
other pathways shown by us and others through genome-wide association studies to be important in IBDpathogenesis (Jostins et al.,
2012; de Lange et al., 2017). These were Toll-like receptor cascades, NOD-signaling, autophagy, unfolded protein response and
epithelial cell-cell junctions. We included the PIP3/AKT signaling pathways as it is downstream of many of the pathways defined
above and we had discovered two large scale deletions affecting genes in this pathway before performing the analysis. Finally,
we defined a list of genes known to cause early-onset, monogenic forms of IBD. Many of the genes defined in the literature affect
myeloid cell development and cause severe immunodeficiencies (Uhlig, 2013; Uhlig et al., 2014). We restricted our analysis to the
union of monogenic-IBD genes which either are specifically thought to affect epithelial cells or were members of any of the pathways
above.
We extracted global dN/dS values formissense and truncating variants for each of the 15 pathways/gene sets (Figure 6C; Table S6)
separately and used the Benjamini-Hochberg method to correct for a total of 30 tests.Cell 182, 672–684.e1–e5, August 6, 2020 e5
Supplemental Figures
Figure S1. Clonality, Coverage, and Sensitivity of Crypts and Mutations Calls, Related to Figure 1
(A) The median variant allele fraction (VAF) of mutations called in each crypt.
(B) The median coverage of sequenced crypts.
(C) Internal analysis of CaveMan sensitivity. The dashed lines show interpolation of the sensitivity given the median coverage of cases (18.2X - 97% sensitivity)
and controls (16.3X - 95% sensitivity). The yellow dots represent biological duplicates where sensitivity was estimated by dissecting and sequencing the same
crypts twice (STAR Methods).
(D) VAFs of variants called in crypts that were sequenced twice (referred to as sample 1). Each dot represents a variant. The VAFs are compared against variants




Figure S2. Features of Mutational Signatures Extracted, Related to Figure 2
(A) Cosine-similarities between mutational signatures extracted by hdp compared with published PCAWG signatures.
(B) Correlations between identified signatures.
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Figure S3. Phylogenetic Trees for All Crohn’s Disease Patients, Related to Figures 2, 4, and 6
Mutational signatures are overlaid on the trees and putative driver mutations are mapped to the branch in which they occur. Crypts are labeled on the form
PXBY_Z where PX is the patient number, BY the biopsy number (with a,b and c denoting biopsies taken a few millimeters apart from the same site) and Z is the
crypt number. The crypts labeled in red are from never-inflamed regions of the colon.
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Figure S4. Phylogenetic Trees for All Ulcerative Colitis Patients, Related to Figures 2, 4, and 6
Mutational signatures are overlaid on the trees and putative driver mutations are mapped to the branch in which they occur. Crypts are labeled on the form
PXBY_Z where PX is the patient number, BY the biopsy number (with a,b and c denoting biopsies taken a few millimeters apart from the same site) and Z is the
crypt number. The crypts labeled in red are from never-inflamed regions of the colon.
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Figure S5. Driver Mutations and Positive Selection, Related to Figure 6
(A) Burden of the purine-signature, SBS32, as a function of the duration of purine treatment.
(B) Burden of the purine-signature in patients where at least one crypt has over 150 mutations attributed to purine treatment. Large within-patient variation is
apparent.
(C) A lollipop plot showing the location of mutations found in genes that are enriched for non-synonymous coding mutations in the IBD dataset.
(D) Pathway-level dN/dS ratios for mutations in known cancer genes and cellular pathways important in IBD pathogenesis. The plot shows dN/dS for truncating
mutations. Same as Figure 6C but also showing the ratios for controls and ratios obtained when analysis is restricted to Crohn’s disease or ulcerative colitis
crypts. Error bars represent 95% confidence intervals.
(E) same as (D) but showing dN/dS ratios for missense mutations.
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